Nov 24, 2014 at 14:15 | Source: Moneycontrol.com
Sun Pharmaceutical Industries Ltd has informed BSE that the Hon'ble High Court of Gujarat at Ahmedabad, at its hearing held on November 14, 2014, has sanctioned the Scheme of Arrangement in the nature of Merger of Ranbaxy Laboratories Limited with Sun Pharmaceutical Industries Limited.
Nov 24, 2014 at 10:30 | Source: CNBC-TV18
Parag Thakkar of HDFC Securities recommends going long in Cipla.
Nov 24, 2014 at 09:47 | Source: CNBC-TV18
Watch the interview of Parag Thakkar of HDFC Securities with Latha Venkatesh & Sonia Shenoy on CNBC-TV18, in which he shared his readings and outlook on market and specific stocks.
Nov 22, 2014 at 14:25 | Source: PTI
The comments with respect to the Holcim-Lafarge deal need to be submitted to the CCI (Competition Commission of India) within 15 days, along with supporting documents on how the merger can adversely impact the concerned person or entity, the regulator said, adding that it would not consider 'unsubstantiated objections' to the deal.
Nov 21, 2014 at 10:00 | Source: CNBC-TV18
Ajay Srivastava is bullish on cement, tyre, IT and pharma space. Among stocks, Srivastava likes JK Lakshmi, Shree cement, Sun Pharma, Lupin, Tech Mahindra, Infosys and Oracle.
Nov 20, 2014 at 15:27 | Source: Moneycontrol.com
Sun Pharmaceutical Industries has reported a consolidated total income from operations of Rs 4,769.49 crore and a net profit of Rs 1,572.46 crore for the quarter ended Sep '14
Nov 20, 2014 at 14:29 | Source: CNBC-TV18
According to Nitin Agrawal - Pharma Analyst at IDFC Securities, Sun Pharma, Lupin and Dr Reddy's labs are the preferred picks.
Nov 20, 2014 at 13:04 | Source: CNBC-TV18
Once the closure of the merger (Sun-Ranbaxy) is done and market begins to take due notice of the benefits that can come through on the acquisition the stock will not look that expensive thereon, says Nitin Agrawal.
Nov 18, 2014 at 19:34 | Source: PTI
These changes would be effective from November 28, 2014. Ranbaxy has been already dropped from NSE's benchmark index, Nifty.
Nov 18, 2014 at 14:55 | Source: Reuters
In the suit filed in the District Court for the District of Columbia, Ranbaxy said the FDA's move violated constitutional rights, exceeded the agency's statutory authority, and was "arbitrary, capricious, and otherwise contrary to law."